Phase II study of adjuvant chemotherapy of OPTIMOX therapy (intermittent FOLFOX regimen) for Stage III colon cancer (including Rectosigmoid cancer).
Phase 2
Recruiting
- Conditions
- Colon cancer (including Rectosigmoid cancer)
- Registration Number
- JPRN-UMIN000003672
- Lead Sponsor
- Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnant or nursing 2.Administering antithrobotic drug within 14 days 3.Medical history of allergy or hypersensitivity reactions. 4.Peripheral neuropathy (CTC AE v3.0 <= Grade1) 5.Active infection 6.Serious complications (renal failure or hepatic failure or heart failure) 7.Interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema. 8.Treated heart disease within 12 months 9.History of mental disturbances or cerebrovascular attack. 10.Watery diarrhea. 11.History of other colorectal cancer (including; sarcoma, carcinoid, lymphoma etc). 12.History of cancer (disease free interval was less than 10 years) 13.Double cancer. 14.Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method